| Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 10520779 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: We investigated the effects of enalapril therapy on plasma tissue factor (TF), tissue factor pathway inhibitor (TFPI) and monocyte chemoattractant protein-1 (MCP-1) levels in patients with acute myocardial infarction. BACKGROUND: Macrophages express TF in human coronary atherosclerotic plaques. Both TF and TFPI are major regulators of coagulation and thrombosis. Monocyte chemoattractant protein-1 is a monocyte and macrophage chemotactic and activating factor. METHODS: In a randomized, double-blind, placebo-controlled study beginning about two weeks after myocardial infarction, 16 patients received four weeks of placebo (placebo group) and another 16 patients received four weeks of enalapril 5 mg daily therapy (enalapril group). We performed blood sampling after administration of the doses. RESULTS: There were no significant differences in the serum angiotensin-converting enzyme (ACE) activity, plasma TF, free TFPI or MCP-1 levels before administration between the enalapril and placebo groups. In the enalapril group, ACE activity (IU/liter) (14.0 before, 5.2 on day 3, 5.8 on day 7, 6.3 on day 28), TF levels (pg/ml) (223, 203, 182, 178) and MCP-1 levels (pg/ml) (919, 789, 790, 803) significantly decreased by day 28. However, the free TFPI levels (ng/ml) (28.2, 26.5, 26.8, 28.4) did not change. These four variables were unchanged during the study period in the placebo group. CONCLUSIONS: This study demonstrated that administration of enalapril reduces the increased procoagulant activity in patients with myocardial infarction associated with inhibition of the activation and accumulation of macrophages and monocytes. |
| | |
Authors:
|
H Soejima; H Ogawa; H Yasue; K Kaikita; K Takazoe; K Nishiyama; K Misumi; S Miyamoto; M Yoshimura; K Kugiyama; S Nakamura; I Tsuji |
Related Documents
:
|
3303889 - Heterogeneous myocardial catecholamine concentrations in patients with congestive heart... 17694799 - Brain natriuretic peptide--the biological marker in the diagnosis of overt congestive h... 9137299 - Rapid assay of plasma brain natriuretic peptide in the assessment of acute dyspnoea. 20434879 - Independent predictors of survival in primary systemic (al) amyloidosis, including card... 19322079 - Incremental value of high-sensitivity c-reactive protein and n-terminal pro-b-type natr... 18971099 - Incremental value of n-terminal pro-brain natriuretic peptide over left ventricle eject... 19892059 - Optimization of the interventricular delay in cardiac resynchronization therapy using t... 9114789 - Evaluation of cardiac rhythm disturbances during extravehicular activity. 2283839 - Ultrastructural alterations of right and left ventricular myocytes in tetralogy of fallot. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 34 ISSN: 0735-1097 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 1999 Oct |
Date Detail:
|
Created Date: 1999-10-27 Completed Date: 1999-10-27 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 983-8 Citation Subset: AIM; IM |
Affiliation:
|
Department of Cardiovascular Medicine, Kumamoto University School of Medicine, Kumamoto City, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Angiotensin-Converting Enzyme Inhibitors / adverse effects, therapeutic use* Anticoagulants / blood Chemokine CCL2 / blood* Double-Blind Method Enalapril / adverse effects, therapeutic use* Enzyme-Linked Immunosorbent Assay Female Humans Lipoproteins / blood Macrophages / drug effects, immunology Male Middle Aged Monocytes / drug effects*, immunology Myocardial Infarction / drug therapy*, immunology Thromboplastin / metabolism* |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Anticoagulants; 0/Chemokine CCL2; 0/Lipoproteins; 0/lipoprotein-associated coagulation inhibitor; 75847-73-3/Enalapril; 9035-58-9/Thromboplastin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. T...
Next Document: Low-level exercise echocardiography detects contractile reserve and predicts reversible dysfunction ...